Data‐driven evaluation of suitable immunogens for improved antibody selection
Protein Science · 2025
DOI: 10.1002/pro.70100 ↗At a glance
Journal article in Protein Science, 2025. Written by Katharina Waury and 5 co-authors. Institution: Department of Computer Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Major MEDLINE topics: Antigens, Antibodies. Cited 1 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: Netherlands eScience Center, Alzheimer Nederland, Horizon 2020.
Abstract (original language)
Antibodies are indispensable in laboratory and clinical applications due to their high specificity and affinity for protein antigens. However, selecting the right protein fragments as immunogens for antibody production remains challenging. Leveraging the Human Protein Atlas, this study systematically evaluates immunogen properties aiming to identify key factors that influence their suitability. Antibodies were classified as successful or unsuccessful based on standardized validation experiments, and the structural and functional properties of their immunogens were analyzed. Results indicated that longer immunogens often resulted in more successful but less specific antibodies. Shorter immunogens (50 residues or fewer) with disordered or unfolded regions at the N‐ or C‐terminus and long coil stretches were more likely to generate successful antibodies. Conversely, immunogens with high beta sheet content, transmembrane regions, or disulfide bridges were associated with poorer antibody performance. Post‐translational modification sites within immunogens appeared to mark beneficial regions for antibody generation. To support antibody selection, a novel R package, immunogenViewer, was developed, enabling researchers to easily apply these insights when immunogen sequences are disclosed. By providing a deeper understanding of immunogen suitability, this study promotes the development of more effective antibodies, ultimately addressing issues of reproducibility and reliability in antibody‐based research. The findings are highly relevant to the research community, as end users often lack control over the immunogen selection process in antibody production. The R package is freely available as part of Bioconductor: https://bioconductor.org/packages/release/bioc/html/immunogenViewer.html .
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Computer Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- AI Technology For Life, Department of Information and Computing Science, and Department of Biology, Utrecht University, Utrecht, The Netherlands.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
- UK Dementia Research Institute at UCL, London, UK.
ORCID profiles: Katharina Waury, Hlin Kvartsberg, Henrik Zetterberg, Kaj Blennow, Charlotte E Teunissen, Sanne Abeln
Funding
- Netherlands eScience Center
- Alzheimer Nederland
- Horizon 2020
- Swedish Research Council
- Alzheimerfonden
- Hjärnfonden
- ALF-agreement
- EU Joint Programme - Neurodegenerative Disease Research
Cite
APA
Waury, K., Kvartsberg, H., Zetterberg, H., Blennow, K., Teunissen, C. E., & Abeln, S. (2025). Data‐driven evaluation of suitable immunogens for improved antibody selection. Protein Science. https://doi.org/10.1002/pro.70100
Vancouver
Waury K, Kvartsberg H, Zetterberg H, Blennow K, Teunissen CE, Abeln S. Data‐driven evaluation of suitable immunogens for improved antibody selection. Protein Science. 2025. doi:10.1002/pro.70100
BibTeX
@article{Waury2025,
author = {Waury, Katharina and Kvartsberg, Hlin and Zetterberg, Henrik and Blennow, Kaj and Teunissen, Charlotte E and Abeln, Sanne},
title = {Data‐driven evaluation of suitable immunogens for improved antibody selection},
journal = {Protein Science},
year = {2025},
doi = {10.1002/pro.70100}
}
EUVIMED